Contingency management to promote treatment engagement in comorbid alcohol use disorder and alcohol‐related liver disease: Findings from a pilot randomized controlled trial

Alcohol Clinical and Experimental Research, Journal Year: 2025, Volume and Issue: unknown

Published: March 10, 2025

Abstract Background Alcohol‐related liver disease (ARLD) is a leading cause of preventable death and health inequalities. Evidence‐based interventions for comorbid alcohol use disorder (AUD) ARLD remain limited, only small proportion this clinical population engages with treatment. There need to improve patient outcomes by bridging gap through novel, person‐centred interventions. Contingency management (CM) psychosocial intervention that involves gradual, increasing incentives upon the completion treatment‐related goals, such as treatment attendance. This single‐centre, randomized pilot trial voucher‐based CM was conducted promote engagement in AUD ARLD. Methods Thirty service users were recruited from an inpatient setting, offered integrated care (ILC) allocated ILC or + CM. Primary included feasibility criteria (recruitment, study retention post‐randomization, completeness data protocol fidelity). Secondary outcome on engagement, intake, function also collected. Data gathered at baseline, post‐ILC, 12 weeks post‐ILC analyzed descriptive statistics. Results The research subject challenges inherent conducting applied real‐world setting. recruitment rates 73.20% 36.70%, respectively. All participants received per protocol. An trend observed compared (67% vs. 33%). A trending 76% reduction intake overall improvement among engaging trial, no significant differences between control groups. Conclusion Overall, feasible deliver appears promising improving individuals Aspects related recruitment, fidelity be further adapted before proceeding definitive trial.

Language: Английский

---

Demographic and clinical characteristics associated with utilization of alcohol use disorder treatment in a multicenter study of patients with alcohol‐associated cirrhosis

Alcohol Clinical and Experimental Research, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 4, 2024

Abstract Background Alcohol use disorder (AUD) treatment can help improve clinical outcomes among patients with alcohol‐associated cirrhosis but is underutilized. Among socioeconomically disadvantaged cirrhosis, we examined rates of lifetime and past 12‐month AUD utilization associated demographic characteristics. Methods Racial/ethnically diverse who had at least one hepatology clinic visit in the prior 6 months were recruited from three Northern California medical centers serving veterans safety‐net populations. Participants self‐reported their utilization, liver disease quality life (LDQoL), history current symptoms anxiety depression, problematic drinking as measured by Use Disorders Identification Test (AUDIT). Clinical measures including severity captured records. Results 196 participants, majority male (88%) a mean age 62 years. Two‐thirds participants (67%) reported ever utilizing 32% 12 months. Compared those did not utilize treatment, utilized or younger, lower LDQoL scores, higher scores on anxiety, drinking. In multivariable analyses, odds pharmacological alone both behavioral (vs. none) older LDQoL, anxiety/depressive disorder. For age, clinically significant anxiety/depression Conclusions Patients younger more likely to treatment. To targeted outreach less receive care provision integrated ALD warranted.

Language: Английский

---

Enhancing alcohol use disorder care in alcohol‐associated liver disease: Patient perspectives and systemic barriers

Alcohol Clinical and Experimental Research, Journal Year: 2024, Volume and Issue: 48(11), P. 2000 - 2003

Published: Sept. 18, 2024

Language: Английский

---

Reply to ‘An expert panel Consensus Statement on ALD without experts by experience’

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2024, Volume and Issue: 21(12), P. 886 - 886

Published: Oct. 14, 2024

Language: Английский

---